• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Bafnaph Share Price

    Bafna Pharmaceuticals Share PriceBafna Pharmaceuticals

    Small Cap 3.4k Result
    ₹89.55
    1.85 (2.11%)
    As on 03 December, 2023 | 07:43 BSE: 532989 NSE: BAFNAPHISIN: INE878I01022

    Bafna Pharmaceuticals Performance

    Day Range

    • Low 87.80
    • High 90.95
    ₹ 89.55

    52 Week Range

    • Low 77.05
    • High 124.45
    ₹ 89.55
    • Open Price88.80
    • Previous Close87.70
    • Volume8442

    Start SIP in Bafna Pharmaceuticals

    Start SIP

    Bafna Pharmaceuticals Share Price

    • Over 1 Month 3.17%
    • Over 3 Month -12.63%
    • Over 6 Month -20.72%
    • Over 1 Year -13.02%

    Bafna Pharmaceuticals Key Statistics

    P/E Ratio 12.3
    PEG Ratio 0
    Market Cap Cr 212
    Price to Book Ratio 2.9
    EPS 4.7
    Dividend 0
    Relative Strength Index 55.72
    Money Flow Index 74.92
    MACD Signal -0.54
    Average True Range 3.96

    Bafna Pharmaceuticals Investment Rating

    • Master Rating:

    • Bafna Pharmaceuticals has an operating revenue of Rs. 159.09 Cr. on a trailing 12-month basis. An annual revenue growth of 36% is outstanding, Pre-tax margin of 10% is healthy, ROE of 15% is good. The company has a reasonable debt to equity of 11%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 28% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 89 which is a GOOD score indicating consistency in earnings, a RS Rating of 9 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 64 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Bafna Pharmaceuticals Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 41424234221715
    Operating Expenses Qtr Cr 37363531191516
    Operating Profit Qtr Cr 468432-1
    Depreciation Qtr Cr 1121111
    Interest Qtr Cr 0111000
    Tax Qtr Cr 0000000
    Net Profit Qtr Cr 265321-1
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 11987
    Operating Expenses Annual Cr 10074
    Operating Profit Annual in Cr 1611
    Depreciation Cr 55
    Interest Annual Cr 21
    Tax Annual Cr 00
    Net Profit Annual Cr 115
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 58
    Cash from Investing Activity Annual Cr -7-5
    Cash from Financing Annual Activity Cr 10-4
    Net Cash Flow Annual Cr 8-2
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 7363
    Fixed Assets Annual Cr 4239
    Total Non Current Assets Annual Cr 4239
    Total Current Assets Annual Cr 8751
    Total Assets Annual Cr 13090
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 3127
    ROE Annual % 158
    ROCE Annual % 1611
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1616
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr
    Operating Expenses Qtr Cr
    Operating Profit Qtr Cr
    Depreciation Qtr Cr
    Interest Qtr Cr
    Tax Qtr Cr
    Net Profit Qtr Cr
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr
    Operating Expenses Annual Cr
    Operating Profit Annual in Cr
    Depreciation Cr
    Interest Annual Cr
    Tax Annual Cr
    Net Profit Annual Cr
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr
    Cash from Investing Activity Annual Cr
    Cash from Financing Annual Activity Cr
    Net Cash Flow Annual Cr
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr
    Fixed Assets Annual Cr
    Total Non Current Assets Annual Cr
    Total Current Assets Annual Cr
    Total Assets Annual Cr
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs
    ROE Annual %
    ROCE Annual %
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin %
    Invest in Bafna Pharmaceuticals

    Bafna Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹89.55
    1.85 (2.11%)
    pointer
    • Bullish Moving Average
    • ___
    • 11
    • Bearish Moving Average
    • ___
    • 5
    • 20 Day
    • ₹86.74
    • 50 Day
    • ₹88.13
    • 100 Day
    • ₹90.08
    • 200 Day
    • ₹94.24
    • 20 Day
    • ₹85.64
    • 50 Day
    • ₹88.98
    • 100 Day
    • ₹90.59
    • 200 Day
    • ₹92.86

    Bafna Pharmaceuticals Resistance and Support

    PIVOT
    ₹89.44
    Resistance
    First Resistance 91.07
    Second Resistance 92.58
    Third Resistance 94.22
    RSI 55.72
    MFI 74.92
    MACD Single Line -0.54
    MACD 0.23
    Support
    First Resistance 87.92
    Second Resistance 86.28
    Third Resistance 84.77

    Bafna Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 8,776 877,600 100
    Week 31,770 3,177,025 100
    1 Month 17,127 1,712,681 100
    6 Month 6,813 681,285 100

    Bafna Pharmaceuticals Result Highlights

    Bafna Pharmaceuticals Synopsis

    NSE-Medical-Generic Drugs

    Bafna Pharmaceutical belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 115.35 Cr. and Equity Capital is Rs. 23.66 Cr. for the Year ended 31/03/2023. Bafna Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/03/1995 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L24294TN1995PLC030698 and registration number is 030698.
    Market Cap 212
    Sales 159
    Shares in Float 0.26
    No of funds
    Yield
    Book Value 2.88
    U/D Vol ratio 0.5
    LTDebt / Equity 11
    Alpha -0.03
    Beta 0.07

    Bafna Pharmaceuticals

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 88.74%90%90%90.02%
    Foreign Portfolio Investors
    Individual Investors 6.87%5.64%5.63%5.61%
    Others 4.39%4.36%4.37%4.37%

    Bafna Pharmaceuticals Management

    Name Designation
    Mrs. S Hemalatha Chairperson & Executive Director
    Mrs. Akila C Raju Non Exe.Non Ind.Director
    Ms. R Chitra Ind. Non-Executive Director
    Mr. B Kamlesh Kumar Ind. Non-Executive Director
    Mr. P K Sundaresan Ind. Non-Executive Director

    Bafna Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Bafna Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2023-11-09 Quarterly Results
    2023-08-11 Quarterly Results
    2023-05-27 Audited Results (Revised)
    2023-04-07 Others
    2023-02-08 Quarterly Results

    Bafna Pharmaceuticals FAQs

    What is Share Price of Bafna Pharmaceuticals ?

    Bafna Pharmaceuticals share price is ₹89 As on 03 December, 2023 | 07:29

    What is the Market Cap of Bafna Pharmaceuticals ?

    The Market Cap of Bafna Pharmaceuticals is ₹211.8 Cr As on 03 December, 2023 | 07:29

    What is the P/E ratio of Bafna Pharmaceuticals ?

    The P/E ratio of Bafna Pharmaceuticals is 12.3 As on 03 December, 2023 | 07:29

    What is the PB ratio of Bafna Pharmaceuticals ?

    The PB ratio of Bafna Pharmaceuticals is 2.9 As on 03 December, 2023 | 07:29

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.